Rep. David Taylor Sells Off Shares of Amgen Inc. (NASDAQ:AMGN)

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on November 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on November 3rd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/5/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 11/5/2026.
• Sold $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 11/3/2026.

Amgen Stock Down 0.3%

Shares of AMGN stock traded down $1.39 during trading hours on Friday, reaching $465.67. The company had a trading volume of 2,122,101 shares, compared to its average volume of 2,720,013. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The business has a fifty day simple moving average of $425.31 and a 200-day simple moving average of $381.17. The company has a market cap of $251.89 billion, a price-to-earnings ratio of 27.01, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same quarter in the prior year, the business posted $5.64 EPS. The business’s revenue was up 8.5% compared to the same quarter last year. On average, research analysts expect that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen’s dividend payout ratio is 58.47%.

Top Amgen Stories

These are some of the AMGN stories that stood out recently:

• Neutral Sentiment: A comparison of Amgen and Vertex highlights Amgen’s broad global footprint and diversified medicines portfolio, but offers no clear near-term catalyst for the shares. Article
• Neutral Sentiment: A Trefis article examines Amgen’s valuation relative to peers, but the provided summary does not include its conclusion. Article
• Negative Sentiment: One report puts the consensus price target at $422.76, below the recent reference price of $465.67; that gap could temper sentiment despite Argus’ more bullish forecast. Article

Analyst Ratings Changes

A number of brokerages recently commented on AMGN. Oppenheimer reaffirmed an “outperform” rating on shares of Amgen in a research report on Friday, October 23rd. BMO Capital Markets decreased their target price on Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research report on Monday, October 12th. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Wednesday, November 4th. Robert W. Baird boosted their price target on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group raised their price objective on shares of Amgen from $384.00 to $440.00 and gave the stock a “hold” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $424.66.

Institutional Trading of Amgen

A number of hedge funds and other institutional investors have recently made changes to their positions in AMGN. Quest 10 Wealth Builders Inc. lifted its holdings in shares of Amgen by 220.0% in the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock worth $34,000 after buying an additional 55 shares in the last quarter. Wellington Altus USA Inc. grew its stake in Amgen by 72.3% during the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 34 shares in the last quarter. Nvwm LLC grew its stake in Amgen by 412.5% during the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 66 shares in the last quarter. PFS Partners LLC increased its holdings in Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after acquiring an additional 42 shares during the period. Finally, TOWER TRUST & INVESTMENT Co bought a new stake in Amgen during the 3rd quarter worth approximately $38,000. 76.50% of the stock is currently owned by institutional investors.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.